Shanghai AbelZeta

Shanghai AbelZeta, based in Shanghai, China, is a cell therapy company. AbelZeta Pharma is a global cell therapy company focused on discovering, developing and manufacturing CAR-T therapeutics for haematologic malignancies, inflammatory and immunological diseases, and solid tumours. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials in hepatocellular carcinoma and multiple myeloma. The largest, NCT06590246 (A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)), plans to enrol 121 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.